TP53 and cancer: Nevertheless, three driver genes (that is, TP53, CDKN2A and TERT) showed a metastatic enrichment across multiple cancer types (Fig. 4b), indicating that alterations of these genes may enhance aggressiveness by disturbing pan-cancer hallmarks of tumorigenesis.